Lichen planopilaris and pseudopelade of Brocq involve distinct disease associated gene expression patterns by microarray

Journal of Dermatological Science

Volumn 57, Issue 1, 2010, Pages 27-36

  Yu, Mei ^a,b   Bell, Robert H ^c   Ross, Elizabeth K ^a   Lo, Blanche K K ^a   Isaac Renton, Megan ^a   Martinka, Magda ^a   Haegert, Anne ^c   Shapiro, Jerry ^a   McElwee, Kevin J ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Cicatricial alopecia; Lichen planopilaris; Microarray; Pseudopelade of Brocq

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN; APOLIPOPROTEIN L2; APRIL PROTEIN; BINDING PROTEIN; COMPLEMENT COMPONENT C5A; COMPLEMENTARY DNA; DEAD BOX PROTEIN; ENDOTHELIN B RECEPTOR; EPHRIN B3; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 5; STROMELYSIN 3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ZINC FINGER PROTEIN;

ALOPECIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LICHEN PLANOPILARIS; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOPELADE OF BROCQ; SIGNAL TRANSDUCTION; SKIN BIOPSY;

ALOPECIA; ANIMALS; BIOPSY; CLUSTER ANALYSIS; FALSE POSITIVE REACTIONS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LICHEN PLANUS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; SCALP; SKIN;

EID: 72149090894     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.10.011     Document Type: Article

References (49)

1. Whiting D.A. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol 19 (2001) 211-225
2. Wu W.Y., Otberg N., McElwee K.J., and Shapiro J. Diagnosis and management of primary cicatricial alopecia: part II. SKINmed 7 (2008) 78-83
3. Otberg N., Wu W.Y., McElwee K.J., and Shapiro J. Diagnosis and management of primary cicatricial alopecia: part I. SKINmed 7 (2008) 19-26
4. Moresi J.M., and Horn T.D. Distribution of Langerhans cells in human hair follicle. J Cutan Pathol 24 (1997) 636-640
5. McElwee K.J. Etiology of cicatricial alopecias: a basic science point of view. Dermatol Ther 21 (2008) 212-220
6. Ross E.K., Tan E., and Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol 53 (2005) 1-37 quiz 38-40
7. Ronchese F. Pseudopelade. Arch Dermatol 82 (1960) 336-343
8. Laymon C.W., and Murphy R.J. The cicatricial alopecias: an historical and clinical-review and an histologic investigation. J Invest Dermatol 8 (1947) 99-122
9. Braun-Falco O., Imai S., Schmoeckel C., Steger O., and Bergner T. Pseudopelade of Brocq. Dermatologica 172 (1986) 18-23
10. Pierard-Franchimont C., and Pierard G.E. Massive lymphocyte-mediated apoptosis during the early stage of pseudopelade. Dermatologica 172 (1986) 254-257
11. Dawber R. What is pseudopelade?. Clin Exp Dermatol 17 (1992) 305-306
12. Photinos P.L. Pseudopelade de Brocq (1930), Maloire Publishers, Paris
13. Nayar M., Schomberg K., Dawber R.P., and Millard P.R. A clinicopathological study of scarring alopecia. Br J Dermatol 128 (1993) 533-536
14. Amato L., Mei S., Massi D., Gallerani I., and Fabbri P. Cicatricial alopecia; a dermatopathologic and immunopathologic study of 33 patients (pseudopelade of Brocq is not a specific clinico-pathologic entity). Int J Dermatol 41 (2002) 8-15
15. Amato L., Massi D., Berti S., Moretti S., and Fabbri P. A multiparametric approach is essential to define different clinicopathological entities within pseudopelade of Brocq: reply from authors. Br J Dermatol 146 (2002) 532-533
16. Degos R., Rabut R., Duperrat B., and Leclercq R. Pseudopeladic state; comments on one hundred cases of circumscribed cicatricial alopecia, apparently primary, of pseudopelade type. Ann Dermatol Syphiligr (Paris) 81 (1954) 5-26
17. Lyons P. Advances in spotted microarray resources for expression profiling. Brief Funct Genomic Proteomic 2 (2003) 21-30
18. Nelson C.C., Hoffart D., Gleave M.E., and Rennie P.S. Application of gene microarrays in the study of prostate cancer. Methods Mol Med 81 (2003) 299-320
19. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98 (2001) 5116-5121
20. Harris M.A., Clark J., Ireland A., Lomax J., Ashburner M., Foulger R., et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32 (2004) D258-261
21. Huang da W., Sherman B.T., Tan Q., Collins J.R., Alvord W.G., Roayaei J., et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8 (2007) R183
22. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., et al. A network-based analysis of systemic inflammation in humans. Nature 437 (2005) 1032-1037
23. Bachmeier B.E., Boukamp P., Lichtinghagen R., Fusenig N.E., and Fink E. Matrix metalloproteinases-2,-3,-7 -9 and -10, but not MMP-11, are differentially expressed in normal, benign tumorigenic and malignant human keratinocyte cell lines. Biol Chem 381 (2000) 497-507
24. Demedts I.K., Brusselle G.G., Bracke K.R., Vermaelen K.Y., and Pauwels R.A. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 5 (2005) 257-263
25. Odaka C., and Izumiyama S. Expression of stromelysin-3 (matrix metalloproteinase-11) in macrophages of murine thymus following thymocyte apoptosis. Cell Immunol 235 (2005) 21-28
26. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6 (1990) 121-125
27. Chen W.T. Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 4 (1992) 802-809
28. Anglard P., Melot T., Guerin E., Thomas G., and Basset P. Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem 270 (1995) 20337-20344
29. Nakopoulou L., Lazaris A.C., Boletis I., Michail S., Iatrou C., Papadakis G., et al. The expression of matrix metalloproteinase-11 protein in various types of glomerulonephritis. Nephrol Dial Transplant 22 (2007) 109-117
30. Cribier B., Noacco G., Peltre B., and Grosshans E. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 46 (2002) 408-413
31. Wolf C., Chenard M.P., Durand de Grossouvre P., Bellocq J.P., Chambon P., and Basset P. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 99 (1992) 870-872
32. Wang C.S., and Tetu B. Stromelysin-3 expression by mammary tumor-associated fibroblasts under in vitro breast cancer cell induction. Int J Cancer 99 (2002) 792-799
33. Kasper G., Reule M., Tschirschmann M., Dankert N., Stout-Weider K., Lauster R., et al. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway. BMC Cancer 7 (2007) 12
34. Kossakowska A.E., Huchcroft S.A., Urbanski S.J., and Edwards D.R. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73 (1996) 1401-1408
35. Gates A.H., and Karasek M. Hereditary absence of sebaceous glands in the mouse. Science 148 (1965) 1471-1473
36. Gates A.H., Arundell F.D., and Karasek M.A. Hereditary defect of the pilosebaceous unit in a new double mutant mouse. J Invest Dermatol 52 (1969) 115-118
37. Williams D., and Stenn K.S. Transection level dictates the pattern of hair follicle sheath growth in vitro. Dev Biol 165 (1994) 469-479
38. Stenn K.S. Insights from the asebia mouse: a molecular sebaceous gland defect leading to cicatricial alopecia. J Cutan Pathol 28 (2001) 445-447
39. Porter R.M., Jahoda C.A., Lunny D.P., Henderson G., Ross J., McLean W.H., et al. Defolliculated (dfl): a dominant mouse mutation leading to poor sebaceous gland differentiation and total elimination of pelage follicles. J Invest Dermatol 119 (2002) 32-37
40. Karnik P., Tekeste Z., McCormick T.S., Gilliam A.C., Price V.H., Cooper K.D., et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 129 (2009) 1243-1257
41. Page N.M., Butlin D.J., Lomthaisong K., and Lowry P.J. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 74 (2001) 71-78
42. Vanhollebeke B., and Pays E. The function of apolipoproteins L. Cell Mol Life Sci 63 (2006) 1937-1944
43. Takahashi S., Cui Y.H., Han Y.H., Fagerness J.A., Galloway B., Shen Y.C., et al. Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. Schizophr Res 104 (2008) 153-164
44. Mimmack M.L., Ryan M., Baba H., Navarro-Ruiz J., Iritani S., Faull R.L., et al. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci USA 99 (2002) 4680-4685
45. Mackay F., and Schneider P. Cracking the BAFF code. Nat Rev Immunol 9 (2009) 491-502
46. Sutherland A.P., Mackay F., and Mackay C.R. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 112 (2006) 774-786
47. Mackay F., and Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 18 (2006) 284-289
48. Sun J., Lin Z., Feng J., Li Y., and Shen B. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol 597 (2008) 1-5
49. Ramanujam M., and Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?. Immunol Rev 223 (2008) 156-174